Dupixent improves BP remission rate fivefold in pivotal trial, potentially leading to regulatory approval.
Dupixent (dupilumab) has shown remarkable efficacy in a pivotal trial for bullous pemphigoid (BP), a serious skin disease. In the ADEPT study, patients receiving Dupixent were five times more likely to achieve sustained disease remission compared to those on placebo. This treatment's success may lead to regulatory approvals in the U.S. and Europe, offering a new option for BP management and potentially reducing reliance on steroids.
September 11, 2024
12 Articles